Bharat Biotech International Limited (BBIL), the developer of India’s first indigenous Covid-19 vaccine Covaxin, on Tuesday said it has inked a memorandum of understanding (MoU) with the University of Sydney Infectious Diseases Institute (Sydney ID) to collaborate on advancing vaccine research initiatives, strengthening academic-industry partnerships and augmenting global efforts to combat infectious diseases.
Bharat Biotech, Sydney University ink MoU to collaborate on vaccine R&D & infectious diseases
- Thread starter hanuman
- Start date